# Jiangsu Vcare

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-vcare

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.vcarepharmatech.com
- Total disclosed funding: $149M
- Latest round: Series C (Jun 2, 2026)
- Investors on record: 13

## About

Based in Nanjing, China and founded in 2010, Jiangsu Vcare Pharmatech Co., Ltd., trading as Jiangsu Vcare, operates as a pharmaceutical technology company that focuses on the research and development of chemical drugs. It was recognized as the National High-tech Enterprise. The company has a production base in Xiangyang. In 2017, the company completed the acquisition of the Nantong API plant. In June 2026, Jiangsu Vcare raised approximately CNY 200 million in Series C3 funding led by Hongcheng Investment Management, with participation from Hangzhou Jinlong Group, Xinghe Ventures, Hongyao Science and Technology, Hangzhou Huadian Investment Management Co., Ltd., Huafu Ruixing Capital Management Co., Ltd. and other investors.

The company mainly provides Generic drugs, APIs (Active Pharmaceutical Ingredient), impurities in APIs, and other intermediates. Its main products include VC004, Vicagrere capsules and VC005. VC004 is a class 1 targeted antitumor drug and belongs to the second generation of Trk (tropomyosin receptor kinase) inhibitors. Vcare Pharmatech has established a targeted innovation development platform, computer-aided drug design platform, drug synthesis and separation technology platform. The company also provides pharmaceutical services, clinical services, chemistry CDMO (contract development and manufacturing organization) services. The company's drug research and development pipelines cover the fields of cardiovascular, cerebrovascular, tumour, endocrine.

The company generates revenue by providing innovative drugs.

The Series C3 funding raised in June 2026 will be primarily used for in-depth R&D of core innovative drug products, iterative upgrades of its AI artificial intelligence technology platform, and the construction and market expansion of its future commercialization system, thus creating a complete closed loop from drug development to industrialization.

## Funding rounds

- Series C, Jun 2, 2026, $30M — Hangzhou Huadian Investment Management Co., Ltd., Hangzhou Jinlong Group, Hongcheng Investment Management, Hongyao Science and Technology, Xinghe Ventures, Huafu Ruixing Capital Management Co., Ltd.
- Series C, Jan 22, 2025, $27M — Changjiang Industrial Investment, CS Capital, Hangzhou Jinlong Group, Xinghe Ventures
- Series C, Jan 2, 2024, $63M — DYEE Capital, Hangzhou Huadian Investment Management Co., Ltd., China Life Capital, Nanjing Innovation Capital Group, Hongyao Science and Technology
- Series B, Dec 26, 2022, $29M — Changjiang Industrial Investment, CS Capital, Hangzhou Huadian Investment Management Co., Ltd., Hangzhou Changjiang Venture Capital, Hongcheng Investment Management
- Series A, Apr 21, 2022 — China Merchants Capital, Changjiang Industrial Investment

## Investors

- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series A
- Changjiang Industrial Investment — Series A, Series B, Series C
- CS Capital — Series B, Series C
- Hangzhou Huadian Investment Management Co., Ltd. — Series B, Series C
- Hangzhou Changjiang Venture Capital — Series B
- Hongcheng Investment Management (https://capitalatlas.ai/funds/hongcheng-investment-management) — Series B, Series C
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series C
- China Life Capital — Series C
- Nanjing Innovation Capital Group — Series C
- Hongyao Science and Technology — Series C
- Hangzhou Jinlong Group — Series C
- Xinghe Ventures — Series C
- Huafu Ruixing Capital Management Co., Ltd. — Series C